Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | RAF1 | P04049 | 2/20 | 0.81 |
| ▸ | LYN | P07948 | 2/20 | 0.81 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.81 |
| ▸ | EGFR | P00533 | 1/20 | 0.81 |
| ▸ | BRAF | P15056 | 1/20 | 0.81 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.81 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.81 |
| ▸ | AKT1 | P31749 | 1/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.71 |
| ▸ | SRC | P12931 | 11/20 | 0.57 |
| ▸ | GSK3A | P49840 | 10/20 | 0.48 |
| ▸ | SYK | P43405 | 9/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092823 | 0.94 | ABL1 (0.81) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6608310 | 0.93 | ABL1 (0.79) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL7240138 | 0.92 | ABL1 (0.75) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6611632 | 0.92 | ABL1 (0.75) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6608649 | 0.92 | ABL1 (0.74) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6608709 | 0.91 | ABL1 (0.76) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6608850 | 0.91 | ABL1 (0.76) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL6609607 | 0.91 | ABL1 (0.76) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL4087514 | 0.91 | ABL1 (0.75) | ABL1RAF1LYNMAPK9EGFR | |
| Ammonia Solution, Strong SCHEMBL6636506 | 0.91 | ABL1 (0.75) | ABL1RAF1LYNMAPK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381594-A1 | UREA COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | claimed |
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | claimed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | claimed |
| EP-1381594-A1 | UREA COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6608052-B2 | An mono or polycyclic aromatic or heteroaromatic carbamate or urea or thiacarbamoyl derivatives; inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-19 | — | — | US | disclosed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032195-A1 | Compounds useful as anti-inflammatory agents | MPO, EPX, PTGES | ABL1 3903/4885RAF1 2166/4885LYN 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.